A clinician's experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting

European Journal of Heart Failure

Volumn 10, Issue 3, 2008, Pages 260-266

  Alehagen, U ^a   Janzon, M ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Heart failure; Natriuretic peptides; Point of care

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL DECISION MAKING; COMPARATIVE STUDY; DEVICE; DIAGNOSTIC VALUE; DISEASE EXACERBATION; EVALUATION; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CHEMILUMINESCENT MEASUREMENTS; COSTS AND COST ANALYSIS; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC;

EID: 40249097388     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.01.005     Document Type: Article

References (24)

1. Rothenburger M., Wichter T., Schmid C., et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant 23 10 (2004) 1189-1197
2. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105 5 (2002) 595-601
3. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 7 (2004) 647-654
4. Troughton R., Frampton C., Yandle T., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 9210 (2000) 1126-1130
5. Goetze J., Gore A., Moller C., et al. Acute myocardial hypoxia increases BNP gene expression. FASEB J 18 15 (2004) 1928-1930
6. Foote R., Pearlman J., Siegel A., and Yeo K. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 44 10 (2004) 1980-1987
7. James S., Lindahl B., Timmer J., et al. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol 97 2 (2006) 167-172
8. Gosselin R., Owings J., White R., et al. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods. Thromb Haemost 83 5 (2000) 698-703
9. Zugck C., Nelles M., Katus H., et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med 44 10 (2006) 1269-1277
10. Kost G., Ehrmeyer S., Chernow B., et al. The laboratory-clinical interface: point-of-care testing. Chest 115 4 (1999) 1140-1154
11. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 230 (1999) 177-181
12. Sokoll L., Baum H., Collinson P., et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 42 8 (2004) 965-972
13. Passing H. Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 21 11 (1983) 709-720
14. Bland J., and Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 8476 (1986) 307-310
15. Alehagen U., Goetze J., and Dahlstrom U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta 382 1-2 (2007) 8-14
16. James S., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 3 (2003) 275-281
17. Grabowski M., Filipiak K., Malek L., et al. Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. Int J Cardiol 115 3 (2006) 386-390
18. Bibbins-Domingo K., Gupta R., Na B., et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. Jama 297 2 (2007) 169-176
19. Tang W., Philip K., Hazen S., et al. Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clinical Cornerstone 7 Suppl 1 (2005) S18-S24
20. Raymond I., Groenning B., Hildebrandt P., et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89 7 (2003) 745-751
21. Jernberg T., James S., Lindahl B., et al. NT-proBNP in unstable coronary artery disease - experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 6 3 (2004) 319-325
22. Januzzi J., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J 27 3 (2006) 330-337
23. Kupchak P., Wu A., Ghani F., et al. Influence of imprecision on ROC curve analysis for cardiac markers. Clin Chem 52 4 (2006) 752-753
24. Hawkridge A., Heublein D., Bergen III H., et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 102 48 (2005) 17442-17447